Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00040469 · ClinicalTrials.gov registry record · Phase 2

Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies

A Phase 2 study, sponsored by Baylor College of Medicine.

Terminated
Registry status
Phase 2
Development phase
15
Enrollment target

NCT00040469: Clinical Trial Phase 2 study, sponsored by Baylor College of Medicine.

NCT00040469 is a Phase 2 study that was terminated before completion, run by Baylor College of Medicine. The registered enrollment target is 15 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00040469, a Phase 2 study, was terminated before completion, sponsored by Baylor College of Medicine.

TERMINATED
Registry status
Phase 2
Development phase
15 participants
Enrollment target

Study Summary

The major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. Participation in this project will be for two years.

Interventions

  • DRUG Cyclophosphamide
  • DRUG Busulfan
  • DRUG Dilantin
  • DRUG Campath -1H

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2000-08
Est. Completion 2003-11-21
Phase Phase 2
Baylor College of Medicine

616 total trials

Why NCT00040469 stopped before completion

NCT00040469 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).

The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.

NCT00040469 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00040469 about?

NCT00040469 is a clinical study titled "Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies". The major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. Participation in this project will be for two years.

What is the current status of trial NCT00040469?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2000-08. Estimated completion is 2003-11-21.

What interventions are being tested in trial NCT00040469?

The interventions under investigation include: Cyclophosphamide (DRUG), Busulfan (DRUG), Dilantin (DRUG), Campath -1H (DRUG).

Who is sponsoring clinical trial NCT00040469?

This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00040469's enrollment target sits among peer trials

15 1919th of 2000 higher than 60 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00040469, the US trial registry maintained by the National Library of Medicine. NCT00040469 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.